This week, we have two interviews: one to mark Childhood Cancer Awareness Month, on osteosarcoma with Paul Romness from OS Therapies; and IMUNON’s CEO, Stacy Lindborg, talking about ovarian cancer, immunotherapy, covid, and more.
Interview times:
02:33 OS Therapies
23:03 IMUNON
Challenging osteosarcoma
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours. OST-HER2, the company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein.
OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency.
The company reported positive data in its phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study.
Ovarian cancer, immunotherapy and more
IMUNON has two DNA-based technology platforms: TheraPlas and PlaCCine. They are designed to use DNA as a therapeutic to code for proteins, which the body can then use to produce medicine where needed.
TheraPlas is designed to harness interleukin-12 (IL-12), a powerful cytokine and well-validated target for cancer immunotherapy, to teach the body’s immune system to fight cancer at the tumour site.
PlaCCine is designed to prompt the body’s immune system to create a vaccine response against infectious diseases such as COVID-19 without needing a virus or device to deliver it.
IMUNON recently announced positive phase 2 data of its IL-12 immunotherapy (IMNN-001) based on TheraPlas technology in advanced ovarian cancer and is currently initiating a phase 3 trial.
Recent phase 1 data of its DNA-based vaccine (IMNN-101) leveraging PlaCCine technology in treatment of COVID-19 indicate that it may be a viable alternative to mRNA vaccines and able to target the Omicron variant as well as any emerging variants in the future, while offering advantages in terms of manufacturing and storage.
We spoke with IMUNON’s CEO, Stacy Lindborg, about the work the company is doing.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
